Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
Provided By GlobeNewswire
Last update: Nov 7, 2024
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported development updates and financial results for its fiscal second quarter ended September 30, 2024.
Read more at globenewswire.com
